Search results
Results From The WOW.Com Content Network
Two systematic reviews identified that indapamide with or without perindopril significantly reduced all cause mortality in young-elderly patients with a history of stroke, cardiovascular disease and type 2 diabetes mellitus, when greater reductions in mean office blood pressure are achieved, significant cardiovascular benefit was only observed ...
Using a fixed combination of an ACE inhibitor and a chlorosulfamoyl diuretic leads to additive synergy of the antihypertensive effects of the two constituents. Its pharmacological properties are derived from those of each of the components taken separately, in addition to those due to the additive synergistic action of the two constituents, when combined, on vascular endothelium ...
With a legacy of more than 100 years, the Better Business Bureau (BBB) is the go-to watchdog for evaluating businesses and charities. The nonprofit organization maintains a massive database of ...
Programs vary by province. In Ontario, for example, most prescriptions for youths under the age of 24 are covered by the Ontario health insurance plan if no private insurance plan is available. [43] Competitive practices such as advertising are kept to a minimum, thus maximizing the percentage of revenues that go directly towards care.
For premium support please call: 800-290-4726 more ways to reach us
National Benefit Authority (NBA) is the largest Disability Tax Credit service provider in Canada, [2] and a founding member of the Association of Canadian Disability Benefit Professionals (ACDBP). Based in Toronto , National Benefit Authority assists clients across Canada in applying for the credit [ 3 ] in exchange for a 30% share of the credit.
The Health Professions Appeal and Review Board (HPARB) is an independent adjudicative agency which reviews decisions made by the 28 self-regulating health professions in Ontario. [1] The Board also holds hearings concerning physicians' hospital privileges under the Public Hospitals Act.
The Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BLA) was a 2005 landmark trial that compared the effects of the established therapy of the combination of atenolol and bendroflumethiazide to the new drug combination of amlodipine and perindopril (trade names Viacoram, AceryCal etc.). [12]